RxDoctor Payments Data

Narian Rajan, MD

Cardiovascular Disease · Alexandria, VANPI 1518905942

Payments from drug & device makers

$2,182in general payments, 2019–2025

Across 30 payments — averaging $72.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$505
  • Boston Scientific$325
  • Medtronic$284
  • AbbVie$235
  • Novartis$220
  • Cardiovascular Systems Inc.$174
  • plus $438 from 6 others

What the payments were for

  • Food & beverage$2,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,182 in reported general payments places this provider in the 55th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$198,622
Medicare patients
2,042
Services billed
3,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$169,053
EntrestoSacubitril/Valsartan113$160,431
JardianceEmpagliflozin63$94,801
XareltoRivaroxaban46$65,548
FarxigaDapagliflozin Propanediol14$21,577
Metoprolol Succinate285$3,189
Rosuvastatin Calcium166$3,017
Atorvastatin Calcium201$1,853
Losartan Potassium163$1,715
Chlorthalidone41$1,024
Nitroglycerin51$927
Ezetimibe39$908
ClopidogrelClopidogrel Bisulfate79$834
Amiodarone Hcl16$786
Spironolactone141$742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$220$160,431113 claims
AstraZenecaFarxiga$20$21,57714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →